Frontier AI firm Profluent has entered a multi-program strategic research collaboration with Eli Lilly and Co. (NYSE:LLY) to develop and commercialize custom site-specific recombinases to treat genetic diseases.

The partnership centers on advancing precise, large-scale DNA editing technologies that conventional gene editing methods have yet to achieve.

Deal Economics And Industry Implications

Financially, Profluent will receive an upfront payment along with committed research and development funding.

The company is also eligible for up to $2.25 billion in milestone payments tied to development and commercialization. There are also tiered royalties on future net sales.

The collaboration reflects increasing pharmaceutical industry interest in AI-enabled platforms.

Read Also:

Also Read: Novo Nordisk Extends Lead As Eli Lilly New Obesity Pill Sees Modest Launch Uptake

Targeting Limitations ...